Ads
related to: celator pharmaceuticals
Search results
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
KTLA-TV Los Angeles· 5 days agoAudio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors ...
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial...
WLNS Lansing· 2 days agoJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from the Phase ...
FDA prioritizes review of Jazz Pharmaceuticals' new cancer therapy By Investing.com
Investing.com· 5 days agoJazz Pharmaceuticals (NASDAQ:JAZZ) announced that the U.S. Food and Drug Administration (FDA) has...
Jazz Pharma share gets buy rating on FDA review news By Investing.com
Investing.com· 5 days agoOn Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) received confirmation of a maintained Buy rating...
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Zacks via Yahoo Finance· 3 days agoA month has gone by since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have lost...
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer - Jazz ...
Benzinga· 5 days agoTarget Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract
ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision
FierceBiotech· 2 days agoAs zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoVANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult
Novartis sues Maryland over law prohibiting restrictions on 340B drugs
Becker’s Hospital Review· 3 days ago"Novartis sues Maryland over new law restricting 340B drug pricing program, citing conflict with federal law and potential harm to constitutional rights."
J&J antidepressant eases symptoms, improves sleep in key trial
BioPharma Dive via Yahoo Finance· 5 days agoThe drug is aimed at a protein, orexin-2, that’s received attention as possible target for treating...
